Table 1. First-line clinical trials for metastatic castrate-resistant prostate cancer selected.
| Trial | Phase | Experimental arm | Control arm | Total (n, %) |
|---|---|---|---|---|
| 20050103a (NCT00321620) |
3 |
Denosumab+Placebo±CT |
Zoledronic+Placebo±CT |
10 (9.9) |
| CA180-227 (NCT00744497) |
3 |
Dasatinib+Docetaxel |
Placebo+Docetaxel |
10 (9.9) |
| CA184-095 (NCT01057810) |
3 |
Ipilimumab |
Placebo |
2 (1.9) |
| CEPO906A2229 (NCT00411528) |
2 |
Patupilone |
Docetaxel 75 |
11 (10.9) |
| FIRSTANA (NCT01308567) |
3 |
Cabazitaxel 25 or 20 |
Docetaxel 75 |
12 (11.8) |
| VENICE (NCT00519285) |
3 |
Aflibercept |
Placebo+Docetaxel |
15 (14.9) |
| E7389-G000-204 (NCT00278993) |
2 |
Eribulin |
None |
14 (13.9) |
| H8Z-MC-JACR (NCT00642018) |
2 |
LY2181308+Docetaxel 75 |
Docetaxel 75 |
10 (9.9) |
| SINERGY (NCT01188187) | 3 | OGX-011+Docetaxel | Docetaxel | 17 (16.8) |
a
Only patients treated with chemotherapy (CT) were included in the analysis. NCT: ClinicalTrials.gov Identifier.